In a real–world setting, 60% of individuals with severe AS and PsA who achieve low disease activity can successfully reduce the dose of TNF inhibitor therapy by a third for a mean of 1 year. PubMed, Rheumatology (Oxford), 06/28/2016. (Also see Ankylosing Spondylitis and Psoriasis and Psoriatic Arthritis)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.